Related references
Note: Only part of the references are listed.Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain
Cristina Trigo-Vicente et al.
EUROPEAN JOURNAL OF HOSPITAL PHARMACY (2020)
Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis-Associated and Idiopathic Chronic Anterior Uveitis
Sheila T. Angeles-Han et al.
ARTHRITIS CARE & RESEARCH (2019)
Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis
Colleen K. Correll et al.
CLINICAL RHEUMATOLOGY (2018)
Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis
Athimalaipet V. Ramanan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Treatment of pediatric uveitis with adalimumab: the MERSI experience
Claudia Castiblanco et al.
JOURNAL OF AAPOS (2016)
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial
Quan Dong Nguyen et al.
LANCET (2016)
Adalimumab in Patients with Active Noninfectious Uveitis
Glenn J. Jaffe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease
Grace K. H. Choi et al.
JOURNAL OF CROHNS & COLITIS (2014)
Does switching anti-TNFα biologic agents represent an effective option in childhood chronic uveitis: The evidence from a systematic review and meta-analysis approach
Gabriele Simonini et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2014)
Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease
Grace K. H. Choi et al.
JOURNAL OF CROHNS & COLITIS (2014)
Share Paper
